Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

Fauci’s memoir, Alnylam’s tenuous trial, and a mid-year review

Can Alnylam find success with its latest cardiac treatment after tweaking the trial? And did STAT’s editorial team pull off a covert mission to get

June 20, 2024

From sewage to safety: Hospital wastewater surveillance as a beacon for defense against H5N1 bird flu

Pandemics start slowly — a few cases here, a few there — until suddenly people are sick or dying everywhere. Early detection by monitoring wastewater

May 1, 2024

INZ-701 by Inozyme Pharma for Rickets: Likelihood of Approval – Pharmaceutical Technology

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.